Skip to Main Content

Paper Details

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Genome Med
15
2016
AKT, APC, BRAF, BRAF p, E1554fs, Gardner syndrome, MAX, MEK, PDC, PDX, PDX model, ROS1, RPTOR, RPTOR mutations, TP53, Wnt/-catenin, children, mTOR, metastatic poorly differentiated carcinoma, patient, poorly differentiated carcinoma, rare tumors, temsirolimus, tumor
Author NameAffiliation
Alberto Ambesi-ImpiombatoColumbia University Medical Center
Mahesh MansukhaniColumbia University Medical Center
Mariano J AlvarezDarwin Health Inc.
Andrea CalifanoColumbia University Medical Center
  • 1 - 4

Datasets

Release 1.2